Earth Science Tech Reports Strong Q3 2026 Results with 341% Net Income Growth

Earth Science Tech, Inc. (OTC: ETST) reported financial and operational results for the third fiscal quarter ended Dec. 31, 2025, with revenue of $8.4 million, up 14.1% year over year, gross profit of $6.4 million reflecting a 76.3% margin, and net income of $910,000, up 341% from the prior-year period. Adjusted EBITDA totaled $1.2 million, total assets increased to $8.1 million, and the company repurchased and retired 3.7 million shares during the first nine months of fiscal 2026, while ending the quarter with $416,000 in cash, $773,000 in working capital and no bank debt as management cited continued operating leverage and expansion initiatives heading into calendar 2026.

The company operates as a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses. The Company’s current operations include compounding pharmaceuticals, telemedicine and real estate development through its wholly owned subsidiaries: RxCompoundStore.com, LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC (“Mister Meds”), and Earth Science Foundation, Inc., Las Villas Health Care, Inc., DOConsultations, LLC., and an 80% interest in MagneChef.

The financial results demonstrate the company's ability to generate substantial profit growth while expanding its revenue base. The 341% increase in net income represents a significant improvement in profitability, while the 76.3% gross margin indicates strong operational efficiency in its business segments. The share repurchase program, which resulted in 3.7 million shares being retired during the first nine months of fiscal 2026, suggests management's confidence in the company's valuation and future prospects.

The debt-free position with $416,000 in cash and $773,000 in working capital provides financial flexibility for continued expansion initiatives. Management's reference to operating leverage suggests the company is achieving economies of scale as it grows, which could lead to further margin expansion in future periods. The company's diversified operations across pharmaceuticals, telemedicine, and real estate development provide multiple growth avenues and risk mitigation through business segment diversification.

Investors can access additional information through the company’s newsroom at https://ibn.fm/ETST. The latest financial results indicate Earth Science Tech is executing on its strategic plan while maintaining strong financial discipline, positioning the company for continued growth as it enters calendar 2026 with momentum from its third quarter performance.